group 11-15 Flashcards
what is immunogen
clinical stage company acquired by abbvie
what is the platform of immunogen
antibody drug conjugates used in cancer treatment
technology and ip of immunogen
targets cancer cells and cancer cells only via the use of cancer-killing toxins conjugated
to cancer cell antibodies
what is fusion pharmaceutical
clinical stage oncology company focused on developing next gen radiopharmaceuticals as precision medecine
what is the platform of fusion pharmaceutical
Targeted Alpha Therapies with Fast-ClearTM Linker technology to connect alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumours
what is macrogenetics
clinical stage biopharmaceutical company
platform of macrogenerics
latform includes multiple antibody technologies – primarily for the treatment of cancer.
o mAbs, ADCs, multi-specific Abs (DART® and TRIDENT®) which includes Next-Gen T-Cell engagers
what is avidity bioscience
clinical stage biopharmaceutical company focused on utilizing their tech to develop rna therapeutics
what is the platform of avidity bioscience
Proprietary Antibody Oligonucleotide Conjugates (AOC ), which combines the specificity of monoclonal
antibodies and the precision of oligonucleotides, to unlock the treatment for rare muscle diseases and for other rare
and common diseases.
what is ascendis pharma
clinical stage biopharmaceutical company that combines technological and therapeutics based approach
what is the platform of ascendis pharma
transcon (transient conjugation) technology
what is the platform of lyell immunopharma
-advanced cellular engineering with proprietary genetic and epigenetic reprogramming technologies
-targeting solid tumors with innovative therapies like lyl979
what is lyell immunopharma
pioneers in t cell programming for the treatment of solid tumors
what is biomarin pharmaceutical
glonal biotech company focused on using genetics and molecular biology to develop for rare disease
what is the tech platform for biomarin pharmaceuticals
-enzyme replacement therapy: providing synthetic copies of missing proteins to people with genetic conditions
-using adeno associated virus gene therapy for dna to cells
what is legend biotech
pioneed and leader in cell therapy
-has global collaboration in china, us, japan and europe
what is the platform for legend biotech
car-t cell therapies to improve cancers such as multiple myeloma
what is precigen inc
discovery and clinical stage biopharmaceutical company
what is the platform for precigen inc
-ultracar-t cells
-focused on the development of gene and cell therapies for immuno-oncology, autoimmune and infectious diseases
-done through precision immunology with a framework of multifunctional therapies designed to work in combination
what is prothena
late stage clinical biotech
what is the platform for prothena
antibodies that target misfolded proteins, small molecules and vaccines
what is alector
clinical stage biopharmaceutical, pioneering immuno-neurology, using insights into human genetics, immunology and neuroscience
what is the platform of alector
monoclonal antibodies
what is intellia
clinical stage biopharmaceutical company
what is the platform for intella
crispr based genome editing technologies for human therapeutic use
what is anavex
clinical stage biopharmaceutical company
what is the platform of anavex
small molecule therapeutics that modulate sigma receptor 1 (sigmar1)
whay is alnylam
biopharmaceutical company
what is the platform of alnylam
Focused on discovering, developing, and commercializing RNAi therapeutics in genetic medicines, cardio-metabolic diseases, infectious diseases, central nervous system, and ocular diseases.
what is ionis
Clinical stage pharmaceutical company specializing in discovery and development of RNA targeted medicines and gene editing to
treat neurological and cardiometabolic diseases
what is platform of ionis
Antisense therapies to target specific mRNAs for degradation to decrease levels of disease-causing protein. In some
cases, antisense therapies may also be used to increase production of deficient mRNAs.
what is arrowhead pharmaceuticals
clinical stahe biopharma company focusing on rnai tech
what is the plastform of arrowhead pharma
rnai molecule trim platform leberages the body’s natural pathway to silence disease causing genes by triggering risc
what is arbutus biopharma
clinical stage biopharmaceutical focused on chronic hep B treatment
what is the platform of arbutus biopharma
combination therapy with rna interference (rnai) therapeutic and oral pd-L1 inhibitor to suppress HBV dna, reduce viral antigens and bost host immune response
what is janux therapeutics
clinical stage biotech focused on the development of improved T cell engagers for the treatment of solid tumor cancers
what is the platform of janux therapeutics
Tumor-Activated T Cell Engager (TRACTr) and Immunomodulator (TRACIr) platforms
* Enhanced specificity, stability, and sensitivity promises reduced limitations of canonical TCEs: CRS, off-target
toxicities, poor PK
what is xencor
clinical stage biopharmaceutical company focused on engineering antibodies and citokines for the treatment of patients with cancer and autoimmune diseases
what is the platform of xencor
-XmAb protein engineering platform
* XmAb Fc Domains augment native immune functions and/or control structure to preserve halflife, stability, and production of antibody treatments
what is merus NV
clinical stage pharmaceutical company
what is the platform of merus NV
-Multiclonics® Technology
o Technology: Developed novel, full length human IgG antibodies capable of binding multiple targets while
maintaining the long half-life and low immunogenicity of conventional monoclonal antibodies
o Created Biclonics® and Triclonics® technologies, through which these antibodies bind 2 or 3 targets,
respectively
what is immunocore
leading biotech company focused on T cell receptor tech to develop therapies for cancer, infectuous diseases and autoimmune disorders
what is the platform of immunocore
-Their novel ImmTAX molecules enhance immune recognition to eliminate infected or cancerous cells.
*KIMMTRAK, the first approved TCR therapy for metastatic uveal melanoma, targets the gp100 antigen.
